Black and White adults' perspectives on the genetics of nicotine addiction susceptibility

Addictive Behaviors

Volumn 36, Issue 7, 2011, Pages 769-772

  Park, Elyse R ^a,b   Kleimann, Susan ^c   Youatt, Emily J ^a   Lockhart, Abigail ^a   Campbell, Eric G ^b   Levy, Douglas E ^a,b   Halbert, Chanita Hughes ^d,e   Schmieder, Erin ^c   Krishna, Rasika ^c   Shields, Alexandra E ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Kleimann Communication Group   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Addiction susceptibility; Genetic testing; Nicotine addiction; Racial differences; Smoking cessation

Indexed keywords

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH BELIEF; HUMAN; MALE; NEGRO; RACE DIFFERENCE; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ALABAMA; ATTITUDE TO HEALTH; BEHAVIOR, ADDICTIVE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MARYLAND; MIDDLE AGED; QUALITATIVE RESEARCH; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 79954928348     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2011.02.007     Document Type: Article

References (49)

1. Andrykowski M.A., Munn R.K., Studts J.L. Interest in learning of personal genetic risk for cancer: A general population survey. Preventive Medicine 1996 Sep-Oct, 25(5):527-536.
2. Audrain-McGovern J., Al Koudsi N., Rodriguez D., Wileyto E.P., Shields P.G., Tyndale R.F. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics 2007 Jan, 119(1):264-274.
3. Batra V., Patkar A.A., Berrettini W.H., Weinstein S.P., Leone F.T. The genetic determinants of smoking. Chest 2003, 123(5):1730-1739.
4. Berrettini W.H., Wileyto E.P., Epstein L., Restine S., Hawk L., Shields P., et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biological Psychiatry 2007, 61(1):111-118.
5. Centers for Disease Control and Prevention Cigarette smoking among adults - United States 2000. MMWR Weekly 2002, 51(29):642-645.
6. Cinciripini P., Wetter D., Tomlinson G., Tsoh J., De Moor C., Cinciripini L., et al. The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood. Nicotine & Tobacco Research 2004, 6(2):229-239.
7. Cokkinides V.E., Halpern M.T., Barbeau E.M., Ward E., Thun M.J. Racial and ethnic disparities in smoking-cessation interventions: Analysis of the 2005 National Health Interview survey. American Journal of Preventive Medicine 2008, 34(5):404-412.
8. Covey L.S., Botello-Harbaum M., Glassman A.H., Masmela J., LoDuca C., Salzman V., et al. Smokers' response to combination bupropion, nicotine patch, and counseling treatment by race/ethnicity. Ethnicity & Disease 2008, 18(1):59-64.
9. Cropsey K.L., Weaver M.F., Eldridge G.D., Villalobos G.C., Best A.M., Stitzer M.L. Differential success rates in racial groups: Results of a clinical trial of smoking cessation among female prisoners. Nicotine & Tobacco Research 2009, 11(6):690-697.
10. Dahl J.P., Jepson C., Levenson R., Wileyto E.P., Patterson F., Berrettini W.H., et al. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. The Pharmacogenomics Journal 2006, 6(3):194-199.
11. Fagan P., Moolchan E.T., Lawrence D., Fernander A., Ponder P.K. Identifying health disparities across the tobacco continuum. Addiction 2007, 102(Suppl 2):5-29.
12. Finch J. The vignette technique in survey research. Sociology 1987, 21:105-114.
13. Fiore M.C. Trends in cigarette smoking in the United States: The epidemiology of tobacco use. The Medical Clinics of North America 1992, 76(2):289-303.
14. Fiore M.C., Novotny T.E., Pierce J.P., Hatziandreu E.J., Patel K.M., Davis R.M. Trends in cigarette smoking in the United States: The changing influence of gender and race. JAMA 1989, 261(1):49-55.
15. Flenaugh E.L., Henriques-Forsythe M.N. Lung cancer disparities in African Americans: Health versus health care. Clinics in Chest Medicine 2006 Sep, 27(3):431-439. vi.
16. Fu S.S., Burgess D., van Ryn M., Hatsukami D.K., Solomon J., Joseph A.M. Views on smoking cessation methods in ethnic minority communities: A qualitative investigation. Preventive Medicine 2007, 44(3):235-240.
17. Fu S.S., Kodl M.M., Joseph A.M., Hatsukami D.K., Johnson E.O., Breslau N., et al. Racial/ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44years. Cancer Epidemiology, Biomarkers & Prevention 2008, 17(7):1640-1647.
18. Gadgeel S.M., Severson R.K., Kau Y., Graff J., Weiss L.K., Kalemkerian G.P. Impact of race in lung cancer: Analysis of temporal trends from a surveillance, epidemiology, and end results database. Chest 2001, 120(1):55-63.
19. Gandhi K.K., Foulds J., Steinberg M.B., Lu S.E., Williams J.M. Lower quit rates among African American and Latino menthol cigarette smokers at a tobacco treatment clinic. International Journal of Clinical Practice 2009, 63(3):360-367.
20. Giovino G.A., Schooley M.W., Zhu B.P., Chrismon J.H., Tomar S.L., Peddicord J.P., et al. Surveillance for selected tobacco-use behaviors-United States, 1900-1994. MMWR CDC Surveillance Summaries 1994, 43(3):1-43. Internet.
21. Haiman C.A., Stram D.O., Wilkens L.R., Pike M.C., Kolonel L.N., Henderson B.E., et al. Ethnic and racial differences in the smoking-related risk of lung cancer. The New England Journal of Medicine 2006, 354(4):333-342.
22. Halbert C.H., Gandy O.H., Collier A., Shaker L. Intentions to participate in genetics research among African American smokers. Cancer Epidemiology, Biomarkers & Prevention 2006, 15(1):150-153.
23. Halbert C.H., Gandy O.H., Collier A., Shaker L. Beliefs about tobacco use in African Americans. Ethnicity & Disease 2007, 17(1):92-98.
24. Hung R.J., McKay J.D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452(7187):633-637.
25. Karp I., O'Loughlin J., Hanley J., Tyndale R.F., Paradis G. Risk factors for tobacco dependence in adolescent smokers. Tobacco Control 2006, 15(3):199-204.
26. Lerman C., Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics 2003, 118B(1):48-54.
27. Lerman C., Caporaso N.E., Audrain J., Main D., Bowman E.D., Lockshin B., et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychology 1999, 18(1):14-20.
28. Lerman C., Caporaso N.E., Audrain J., Main D., Boyd N.R., Shields P.G. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Molecular Psychiatry 2000, 5(2):189-192.
29. Lerman C., Caporaso N.E., Bush A., Zheng Y.L., Audrain J., Main D., et al. Tryptophan hydroxylase gene variant and smoking behavior. American Journal of Medical Genetics 2001, 105(6):518-520.
30. Lerman C., Hughes C., Trock B.J., Myers R.E., Main D., Bonney A., et al. Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 1999, 281(17):1618-1622.
31. Lerman C., Jepson C., Wileyto E.P., Epstein L.H., Rukstalis M., Patterson F., et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmacology 2006, 31(1):231-242.
32. Lerman C., Niaura R. Applying genetic approaches to the treatment of nicotine dependence. Oncogene 2002, 21(48):7412-7420.
33. Lerman C., Shields P.G., Audrain J., Main D., Cobb B., Boyd N.R., et al. The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiology, Biomarkers & Prevention 1998, 7(3):253-255.
34. Lerman C., Wileyto E.P., Patterson F., Rukstalis M., Audrain-McGovern J., Restine S., et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. The Pharmacogenomics Journal 2004, 4(3):184-192.
35. Mogilner A., Otten M., Cunningham J.D., Brower S.T. Awareness and attitudes concerning BRCA gene testing. Annals of Surgical Oncology 1998, 5(7):607-612.
36. Mokdad A.H., Marks J.S., Stroup D.F., Gerberding J.L. Actual causes of death in the United States, 2000. JAMA 2004, 291(10):1238-1245.
37. Munafo M., Johnstone E., Murphy M., Walton R. New directions in the genetic mechanisms underlying nicotine addiction. Addiction Biology 2001, 6(2):109-117.
38. Munafo M.R., Shields A.E., Berrettini W.H., Patterson F., Lerman C. Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 2005, 6(3):211-223.
39. Park E.R., Kleimann S., Pelan J.A., Shields A.E. Anticipating clinical integration of genetically tailored tobacco dependence treatment: Perspectives of primary care physicians. Nicotine & Tobacco Research 2007, 9(2):271-279.
40. Patton M.Q. Qualitative evaluation and research methods 1990, Sage Publications, Inc, Newbury Park, CA. 2nd edition.
41. Peters N., Rose A., Armstrong K. The association between race and attitudes about predictive genetic testing. Cancer Epidemiology, Biomarkers & Prevention 2004, 13(3):361-365.
42. Schnoll R.A., Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opinion on Emerging Drugs 2006, 11(3):429-444.
43. Singh G.K., Miller B.A., Hankey B.F., Edwards B.K. Area socioeconomic variations in U.S. cancer incidence, mortality, stage, treatment, and survival, 1975-1999 2003, National Cancer Institute, Bethesda, MD.
44. Steenland K., Henley J., Thun M. All-cause and cause-specific death rates by educational status for two million people in two American Cancer Society cohorts, 1959-1996. American Journal of Epidemiology 2002, 156(1):11-21.
45. Strauss A., Corbin J. Basics of qualitative research: Grounded theory procedures and techniques 1990, Sage Publications, Inc, Newbury Park, CA.
46. Sullivan P.F., Jiang Y., Neale M.C., Kendler K.S., Straub R.E. Association of the tryptophan hydroxylase gene with smoking initiation but not progression to nicotine dependence. American Journal of Medical Genetics 2001, 105(5):479-484.
47. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452(7187):638-642.
48. Uhl G.R., Liu Q.R., Drgon T., Johnson C., Walther D., Rose J.E., et al. Molecular genetics of successful smoking cessation: Convergent genome-wide association study results. Archives of General Psychiatry 2008, 65(6):683-693.
49. Yoshimasu K., Kiyohara C. Genetic influences on smoking behavior and nicotine dependence: A review. Journal of Epidemiology 2003, 13(4):183-192.